Thermo Scientific Drug Monitoring and Quality Control Products and Instrumentation Multiple technologies

Improve your results

Contents Introduction 8-13 One Resource: Multiple Technologies Collection Devices 16-17 Specimen Collection Kits Flip-Top Containers & Twin Valve Vials Drugs Of Abuse 20 CEDIA/DRI Urine Assays 21 Indiko DAT Reagents 22-23 CEDIA Calibrators 24-25 DRI Calibrators 26-27 CEDIA/DRI Controls 27 MAS DOA Total Controls 28 Instrument References 29-31 Oral Fluids Assays, Reagents, Calibrators & Controls Specimen Validity Tests 32-33 Assays, Reagents, Calibrators & Controls 33 Instrument References Endocrine 34-35 Assays, Reagents, Calibrators & Controls 35 Instrument References Serum Toxicology 36-37 Assays,...

The value of innovation An enduring history of serving science From routine chemistries to highly sensitive tests that will enable the discovery of new biomarkers for disease diagnosis, 21st Century immunoassay techniques are built on the foundation of the radio-immunoassay (RIA). This revolutionary concept was developed for measurement of endogenous plasma insulin by Solomon Berson and Rosalyn Yalow in 1959. Working together as a team, these two scientists proposed the use of the interaction between antibodies and antigens to detect the presence or quantify the concentration of specific analytes...

The limitations of the RIA combined with continued innovation in biomedical research created the perfect environment to take immunoassays in a new direction. The Enzyme Immunoassay (EIA) and the Enzyme-Linked Immunosorbent Assay (ELISA) were envisioned in the 1960s, but it took almost a decade for researchers to demonstrate conclusively that the EIA/ELISA was the next step in building a new generation in immunoassays. These techniques replaced radioisotopes with enzymes in the labeling of antigens and antibodies which could then be detected by spectrophotometric means. The first tests were not...

We never forget That behind every assay performed is a story During the mid 1990s, Thermo Fisher Scientific introduced its DRI® product line. The marketplace reception to these liquid, ready-to-use assays was unparalleled. Increased lab productivity, low cost per test and short turnaround times without sacrificing precision, accuracy and lot-to-lot consistency were right on target with clinical laboratory needs. More recently, we have strengthened our technological leadership with the introduction of the Quantitative Microsphere System (QMS). Our cutting edge Thermo Scientific™ QMS assays are...

decades. The spectrum of our integrated products and services offers both breadth and depth in the areas of drugs of abuse, specimen validity testing and toxicology testing; therapeutic and immunosuppressive drug monitoring; and quality control and data management. The synergy of multiple technologies, a robust menu of homogenous enzyme immunoassays optimized for most clinical chemistry analyzers and the global reach of our customer-responsive training and product support has made Thermo Scientific products the preferred resource for reference and hospital laboratories and other drug monitoring...

One resource Multiple technologies: CEDIA After three decades of application in thousands of laboratories around the world, Thermo Scientific™ CEDIA has proven to be the consummate screening immunoassay for drugs-of-abuse screening, therapeutic drug monitoring, immunosuppressant drug monitoring and toxicology testing. CEDIA® assays are simple to perform, delivering rapid, reliable and inexpensive results and are easily automated for large-volume testing requirements. CEDIA was developed by Microgenics (Thermo Fisher Scientific) in the early 1980s . . . it has proven to be one of the important...

CEDIA offers time-tested technology • Proven track record of reliable results • Trouble-free performance on a wide range of analyzers Broad immunoassay portfolio • One of the largest drugs of abuse test menus in the industry • Customer-responsive therapeutic drug management assay development Multiple sample matrices • Assay samples from urine, oral fluids, serum, plasma and whole blood Excellent correlation to GC/MS • Excellent customer acceptance of stated analyte levels Highly specific monoclonal antibodies • Accurate and specific results • Excellent low-end sensitivity and specificity • Test...

One resource Multiple technologies: DRI A liquid ready-to-use homogeneous enzyme immunoassay – how convenient is that. Add excellent sensitivity, linearity, specificity, precision and accuracy to the mix, and you have a real-world solution that has been proven to reduce costs and increase laboratory productivity without sacrificing quality. DRI technology reduces costs and increases lab productivity without sacrificing quality. Thermo Scientific™ DRI products are proven and trusted testing solutions that offer high analytical accuracy while eliminating time-consuming steps in reagent preparation....

Features DRI offers liquid, ready-to-use reagents. DRI delivers increased laboratory productivity. Reduces cost per test. Technology bio-engineered for automation • Applications for low, medium and high volume laboratories • Assays optimized for most clinical chemistry analyzers • Minimizes unnecessary confirmations • Accurate and specific results • Excellent low-end sensitivity and specificity Excellent open vial stability • Guaranteed consistency: kit-to-kit, lot-to-lot, year-to-year Excellent correlation to GC/MS • Excellent customer acceptance of stated analyte levels Applications available...

One resource Multiple technologies: QMS Thermo Scientific™ QMS (Quantitative Microsphere System) homogeneous assays are the culmination of more than 25 years of research and development in the application of microparticle technology to immunodiagnostics. As pharmaceutical companies continue to develop new drugs and clinicians employ multi-drug treatment regimens, monitoring therapeutic ranges for each drug is becoming critically important. Fortunately, Thermo Fisher Scientific is constantly innovating. By combining decades of experience with comprehensive immunoassay development capabilities,...